enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Dapagliflozin - Wikipedia

   en.wikipedia.org/wiki/Dapagliflozin

   Dapagliflozin is used along with diet, exercise, and usually with other glucose-lowering medications, to improve glycaemic control in adults with type 2 diabetes. . Dapagliflozin, in addition to other SGLT2-inhibitors, was shown to reduce the rate of decline in kidney function and kidney failure in non-diabetic and type 2 diabetic adults when added to the existing treatment

3. SGLT2 inhibitor - Wikipedia

   en.wikipedia.org/wiki/SGLT2_inhibitor

   Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors ...

4. AstraZeneca's Farxiga cuts death risk in heart failure ... - AOL

   www.aol.com/news/astrazenecas-farxiga-cuts-death...

   AstraZeneca's blockbuster diabetes drug Farxiga led to significant reductions in the risk of hospitalisation and death in people with all types of heart failure, according to study data released ...

5. Ozempic, Mounjaro and hundreds of other drugs become even ...

   www.aol.com/finance/ozempic-mounjaro-hundreds...

   Foss, 72, was taking Entresto for heart failure, that costs $185 a month; and Farxiga to prevent kidney failure, with a $145 monthly price tag on her Medicare drug plan. She opted to stop the ...

6. Canagliflozin - Wikipedia

   en.wikipedia.org/wiki/Canagliflozin

   Canagliflozin is indicated to be used with diet and exercise to lower blood sugar in adults with type 2 diabetes; to reduce the risk of major heart-related events such as heart attack, stroke, or death in people with type 2 diabetes who have known heart disease; and to reduce the risk of end-stage kidney disease, worsening of kidney function, heart-related death, and being hospitalized for ...

7. Is oral semaglutide a promising alternative in treating ... - AOL

   www.aol.com/lifestyle/oral-semaglutide-promising...

   New research suggests that the oral version of semaglutide, the active ingredient in injectable drugs like Ozempic, may also help treat diabetes and heart disease. Image credit: Pixel Stories/Stocksy.

8. Sacubitril/valsartan - Wikipedia

   en.wikipedia.org/wiki/Sacubitril/valsartan

   Sacubitril/valsartan, sold under the brand name Entresto among others, is a fixed-dose combination medication for use in heart failure.It consists of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker valsartan.

9. Empagliflozin - Wikipedia

   en.wikipedia.org/wiki/Empagliflozin

   The main efficacy measurement was the time to death from cardiovascular causes or need to be hospitalized for heart failure. [33] Of the individuals who received empagliflozin for an average of about two years, 14% died from cardiovascular causes or were hospitalized for heart failure, compared to 17% of the participants who received the ...